Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Improving Outcomes

Patient Preference and Adherence - New Zealand
doi 10.2147/ppa.s30949
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Pharmacokinetics of Ambrisentan, a Novel Drug for Treatment of Pulmonary Arterial Hypertension (PAH), in Japanese Subjects

Japanese Journal of Clinical Pharmacology and Therapeutics
Pharmacology
2010English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2016English

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

Ambrisentan and Tadalafil Up-Front Combination Therapy in Scleroderma-Associated Pulmonary Arterial Hypertension

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2015English

Future Perspectives for the Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2009English

Surgical Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2002English

Treatment of Pulmonary Arterial Hypertension in Pregnancy

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2007English

Epoprostenol Treatment for Idiopathic Pulmonary Arterial Hypertension in Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy